New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment

Francisco Cervantes, Brigitte Dupriez, Arturo Pereira, Francesco Passamonti, John T. Reilly, Enrica Morra, Alessandro M. Vannucchi, Ruben A. Mesa, Jean Loup Demory, Giovanni Barosi, Elisa Rumi, Ayalew Tefferi

Research output: Contribution to journalArticle

723 Citations (Scopus)

Abstract

Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging because of the increasing use of allogeneic stem cell transplantation and new investigational drugs. To enhance this process by developing a highly discriminative prognostic system, 1054 patients consecutively diagnosed with PMF at 7 centers were studied. Overall median survival was 69 months (95% confidence interval [CI]: 61-76). Multivari- ate analysis of parameters obtained at disease diagnosis identified age greater than 65 years, presence of constitutional symptoms, hemoglobin level less than 10 g/dL, leukocyte count greater than 25 × 10 9/L, and circulating blast cells 1% or greater as predictors of shortened survival. Based on the presence of 0 (low risk), 1 (intermediate risk-1), 2 (intermediate risk-2) or greater than or equal to 3 (high risk) of these variables, 4 risk groups with no overlapping in their survival curves were delineated; respective median survivals were 135, 95, 48, and 27 months (P

Original languageEnglish
Pages (from-to)2895-2901
Number of pages7
JournalBlood
Volume113
Issue number13
DOIs
Publication statusPublished - Mar 26 2009

Fingerprint

Primary Myelofibrosis
Research
Survival
Investigational Drugs
Therapeutics
Stem Cell Transplantation
Stem cells
Leukocyte Count
Decision Making
Hemoglobins
Multivariate Analysis
Decision making
Confidence Intervals

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment. / Cervantes, Francisco; Dupriez, Brigitte; Pereira, Arturo; Passamonti, Francesco; Reilly, John T.; Morra, Enrica; Vannucchi, Alessandro M.; Mesa, Ruben A.; Demory, Jean Loup; Barosi, Giovanni; Rumi, Elisa; Tefferi, Ayalew.

In: Blood, Vol. 113, No. 13, 26.03.2009, p. 2895-2901.

Research output: Contribution to journalArticle

Cervantes, F, Dupriez, B, Pereira, A, Passamonti, F, Reilly, JT, Morra, E, Vannucchi, AM, Mesa, RA, Demory, JL, Barosi, G, Rumi, E & Tefferi, A 2009, 'New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment', Blood, vol. 113, no. 13, pp. 2895-2901. https://doi.org/10.1182/blood-2008-07-170449
Cervantes, Francisco ; Dupriez, Brigitte ; Pereira, Arturo ; Passamonti, Francesco ; Reilly, John T. ; Morra, Enrica ; Vannucchi, Alessandro M. ; Mesa, Ruben A. ; Demory, Jean Loup ; Barosi, Giovanni ; Rumi, Elisa ; Tefferi, Ayalew. / New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment. In: Blood. 2009 ; Vol. 113, No. 13. pp. 2895-2901.
@article{1a9a4e233f584b53a8acbae8149322d5,
title = "New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment",
abstract = "Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging because of the increasing use of allogeneic stem cell transplantation and new investigational drugs. To enhance this process by developing a highly discriminative prognostic system, 1054 patients consecutively diagnosed with PMF at 7 centers were studied. Overall median survival was 69 months (95{\%} confidence interval [CI]: 61-76). Multivari- ate analysis of parameters obtained at disease diagnosis identified age greater than 65 years, presence of constitutional symptoms, hemoglobin level less than 10 g/dL, leukocyte count greater than 25 × 10 9/L, and circulating blast cells 1{\%} or greater as predictors of shortened survival. Based on the presence of 0 (low risk), 1 (intermediate risk-1), 2 (intermediate risk-2) or greater than or equal to 3 (high risk) of these variables, 4 risk groups with no overlapping in their survival curves were delineated; respective median survivals were 135, 95, 48, and 27 months (P",
author = "Francisco Cervantes and Brigitte Dupriez and Arturo Pereira and Francesco Passamonti and Reilly, {John T.} and Enrica Morra and Vannucchi, {Alessandro M.} and Mesa, {Ruben A.} and Demory, {Jean Loup} and Giovanni Barosi and Elisa Rumi and Ayalew Tefferi",
year = "2009",
month = "3",
day = "26",
doi = "10.1182/blood-2008-07-170449",
language = "English",
volume = "113",
pages = "2895--2901",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment

AU - Cervantes, Francisco

AU - Dupriez, Brigitte

AU - Pereira, Arturo

AU - Passamonti, Francesco

AU - Reilly, John T.

AU - Morra, Enrica

AU - Vannucchi, Alessandro M.

AU - Mesa, Ruben A.

AU - Demory, Jean Loup

AU - Barosi, Giovanni

AU - Rumi, Elisa

AU - Tefferi, Ayalew

PY - 2009/3/26

Y1 - 2009/3/26

N2 - Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging because of the increasing use of allogeneic stem cell transplantation and new investigational drugs. To enhance this process by developing a highly discriminative prognostic system, 1054 patients consecutively diagnosed with PMF at 7 centers were studied. Overall median survival was 69 months (95% confidence interval [CI]: 61-76). Multivari- ate analysis of parameters obtained at disease diagnosis identified age greater than 65 years, presence of constitutional symptoms, hemoglobin level less than 10 g/dL, leukocyte count greater than 25 × 10 9/L, and circulating blast cells 1% or greater as predictors of shortened survival. Based on the presence of 0 (low risk), 1 (intermediate risk-1), 2 (intermediate risk-2) or greater than or equal to 3 (high risk) of these variables, 4 risk groups with no overlapping in their survival curves were delineated; respective median survivals were 135, 95, 48, and 27 months (P

AB - Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging because of the increasing use of allogeneic stem cell transplantation and new investigational drugs. To enhance this process by developing a highly discriminative prognostic system, 1054 patients consecutively diagnosed with PMF at 7 centers were studied. Overall median survival was 69 months (95% confidence interval [CI]: 61-76). Multivari- ate analysis of parameters obtained at disease diagnosis identified age greater than 65 years, presence of constitutional symptoms, hemoglobin level less than 10 g/dL, leukocyte count greater than 25 × 10 9/L, and circulating blast cells 1% or greater as predictors of shortened survival. Based on the presence of 0 (low risk), 1 (intermediate risk-1), 2 (intermediate risk-2) or greater than or equal to 3 (high risk) of these variables, 4 risk groups with no overlapping in their survival curves were delineated; respective median survivals were 135, 95, 48, and 27 months (P

UR - http://www.scopus.com/inward/record.url?scp=63849328927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63849328927&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-07-170449

DO - 10.1182/blood-2008-07-170449

M3 - Article

VL - 113

SP - 2895

EP - 2901

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -